The CAPRIE-Like Subgroups of CHARISMA: A CAPRIEciously Biased Analysis of an unCHARISMAtic Truth

Are we to ignore the results of the MATCH (Management of Atherothrombosis With Clopidogrel in High-Risk Patients) trial (5), which showed statistically significant net harm for patients with recent stroke/transient ischemic attack (TIA) treated with clopidogrel plus aspirin versus clopidogrel alone,...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2007-10, Vol.50 (17), p.1704-1704
Main Author: Gebel, James M., MD, MSc, FAHA
Format: Article
Language:English
Subjects:
Aspirin
Aspirin - therapeutic use
Cardiology
Cardiovascular
Cardiovascular disease
Clinical trials
Coronary Artery Disease - complications
Coronary Artery Disease - drug therapy
Drug therapy
Drug Therapy, Combination
Heart attacks
Humans
Hypotheses
Internal Medicine
Mortality
Myocardial Ischemia - etiology
Myocardial Ischemia - prevention & control
Platelet Aggregation Inhibitors - therapeutic use
Randomized Controlled Trials as Topic - methods
Research Design
Stroke
Ticlopidine - analogs & derivatives
Ticlopidine - therapeutic use
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Are we to ignore the results of the MATCH (Management of Atherothrombosis With Clopidogrel in High-Risk Patients) trial (5), which showed statistically significant net harm for patients with recent stroke/transient ischemic attack (TIA) treated with clopidogrel plus aspirin versus clopidogrel alone, in favor of those of an improper post hoc subgroup analysis with less than one-half of the analogous patient population?
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2007.06.049